Four months after losing partner AstraZeneca plc upon mixed cardiovascular data, AtheroGenics Inc. plans to start looking for a new collaborator, as patient enrollment gets underway in a Phase III trial of its oral anti-inflammatory antioxidant drug, AGI-1067, in diabetes.(BioWorld Today)
Four months after losing partner AstraZeneca plc upon mixed cardiovascular data, AtheroGenics Inc. plans to start looking for a new collaborator, as patient enrollment gets underway in a Phase III trial of its oral anti-inflammatory antioxidant drug, AGI-1067, in diabetes.(BioWorld Today)
On the heels of a $15 million Series C financing, Adnexus Therapeutics Inc. filed for an initial public offering, hoping to raise as much as $86 million to fund ongoing work with its anti-angiogenic drug, Angiocept, and other early stage Adnectin-based products. (BioWorld Today)
On the heels of a $15 million Series C financing, Adnexus Therapeutics Inc. filed for an initial public offering, hoping to raise as much as $86 million to fund ongoing work with its anti-angiogenic drug, Angiocept, and other early stage Adnectin-based products. (BioWorld Today)
